Thomas J. McClelland

Thomas J. McClelland

Auto-generated profile, based on publicly available information

Thomas J. McClelland

William Harvey Research Institute, Barts and The London School of Medicine & Dentistry Queen Mary University of London London UK

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2024 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
TDThomas W. Davies
Thomas W. Davies
NWNaomi Watson
Naomi Watson
JPJames J. Pilkington
James J. Pilkington
TMThomas J. McClelland
Thomas J. McClelland
GAGiada Azzopardi
Giada Azzopardi
ZPZudin Puthucheary
Zudin Puthucheary
Background: The efficacy of creatine replacement through supplementation for the optimization of physical function in the population at risk of functional disability is unclear.Methods: We conducted a systematic literature search of MEDLINE, EMBASE, the Cochrane Library, and CINAHL from inception to November 2022. Studies included were randomized controlled trials (RCTs) comparing creatine supplementation with placebos in older adults and adults with chronic disease. The primary outcome was physical function measured by the sit‐to‐stand test after pooling data using random‐effects modeling. We also performed a Bayesian meta‐analysis to describe the treatment effect in probability terms. Secondary outcomes included other measures of physical function, muscle function, and body composition. The risk of bias was assessed using the Cochrane risk‐of‐bias tool.Results: We identified 33 RCTs, comprising 1076 participants. From six trials reporting the primary outcome, the pooled standardized mean difference (SMD) was 0.51 (95% confidence interval [CI]: 0.01–1.00; I2 = 62%; P = 0.04); using weakly informative priors, the posterior probability that creatine supplementation improves physical function was 66.7%. Upper‐body muscle strength (SMD: 0.25; 95% CI: 0.06–0.44; I2 = 0%; P = 0.01), handgrip strength (SMD 0.23; 95% CI: 0.01–0.45; I2 = 0%; P = 0.04), and lean tissue mass (MD 1.08 kg; 95% CI: 0.77–1.38; I2 = 26%; P < 0.01) improved with creatine supplementation. The quality of evidence for all outcomes was low or very low because of a high risk of bias.Conclusion: Creatine supplementation improves sit‐to‐stand performance, muscle function, and lean tissue mass. It is crucial to conduct high‐quality prospective RCTs to confirm these hypotheses (PROSPERO number, CRD42023354929).

22 February 2023 in Journal of Parenteral and Enteral Nutrition
Verified
Journal Article
Open access
TMThomas J. McClelland
Thomas J. McClelland
AFAlexander J. Fowler
Alexander J. Fowler
TDThomas W. Davies
Thomas W. Davies
RPRupert Pearse
Rupert Pearse
JPJohn Prowle
John Prowle
ZPZudin Puthucheary
Zudin Puthucheary
Background: Skeletal muscle wasting is a determinant of physical disability in survivors of critical illness. Intramuscular bioenergetic failure, altered substrate metabolim, and inflammation are likely underpinning mechanisms. We examined the effect of pioglitazone, a peroxisome proliferator–activated receptor γ agonist, on muscle‐related outcomes in adults.Methods: We included randomized controlled trials in which pioglitazone was administered (no dose/dosage restrictions) and muscle‐related outcomes were reported. We searched MEDLINE, CENTRAL, EMBASE, CINAHL, and trial registries. Risk of bias was assessed using RoB 2. Primary outcomes were physical function and symptoms, muscle mass and function, or body composition and muscular compositional change. Secondary outcomes included muscle insulin sensitivity, mitochondrial effects, and intramuscular inflammation.Results: Fourteen studies over 19 publications (n = 474 patients) were included. Lean body mass was unaffected in three studies (n = 126) and increased by 1.8–1.92 kg in two studies (P = 0.02 and 0.003, respectively; n = 48). Pioglitazone was associated with increased peripheral insulin sensitivity (+23%–72%, standardized mean difference of 0.97 from trial start point to end point [95% CI, 0.36–1.58; n = 213]). Treatment reduced intramuscular tumor necrosis factor‐α (TNF‐α) levels (−30%; P = 0.02; n = 29), with mixed effects on serum TNF‐α and intramyocellular lipid concentrations. Treatment increased intramuscular markers of adenosine triphosphate (ATP) biosynthesis (ATP5A [+33%, P ≤ 0.05], ETFA [+60%, P ≤ 0.05], and CX6B1 [+ 33%, P = 0.01] [n = 24]), PGC1α and PGC1β messenger RNA expression (P < 0.05; n = 26), and AMPK phosphorylation (+38%, P < 0.05; n = 26). These data have low‐quality evidence profiles owing to risk of bias.Conclusions: Pioglitazone therapy increases skeletal muscle insulin sensitivity and can decrease intramuscular inflammation.

1 January 1997
Verified
Conference Paper
Closed access
LML.A. Mallette
L.A. Mallette
TMT. McClelland
T. McClelland
NBN. Bhaskar
N. Bhaskar
Unique tests and considerations are required for the space qualification of atomic frequency standards (AFS). AFSs have several advantages (i.e., low drift rate and inherent insensitivity to radiation) over more conventional crystal oscillators, which make them preferred for specialized space applications. These features allow the users to obtain more precision in navigation, timing and for autonomous operation. AFSs are exposed to the usual battery of qualification tests normally prescribed for other flight hardware, but their responses to these environments may be unique. There are several additional tests, not applicable to most electronic hardware, that are required for AFS. These test environments are described and applied to the most desired capability of AFS: frequency stability.

19 December 2025 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
TMThomas J. McClelland
Thomas J. McClelland
ABAdam J. Boulton
Adam J. Boulton
AWAlicia A.C. Waite
Alicia A.C. Waite
ABAndrew J. Boyle
Andrew J. Boyle
LFLuke Flower
Luke Flower
MPMandeep Phull
Mandeep Phull

7 August 2026 in British Journal of Anaesthesia
Verified
Journal Article
Closed access
TMThomas J. McClelland
Thomas J. McClelland
LFLuke Flower
Luke Flower
ABAdam J. Boulton
Adam J. Boulton
MPMandeep Phull
Mandeep Phull

8 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
TMThomas J McClelland
Thomas J McClelland
AFAlexander J Fowler
Alexander J Fowler
TDThomas Davies
Thomas Davies
RPRupert Pearse
Rupert Pearse
JPJohn Prowle
John Prowle
ZPZudin Puthucheary
Zudin Puthucheary
Background: Skeletal muscle wasting is a major determinant of physical functional disability in critical illness survivors, and contributes to post-intensive care syndrome. As yet, no therapies exist to address this major public health issue. Intramuscular bioenergetic failure and inflammation are understood to be the underpinning mechanisms, and carbohydrate and lipid oxidation are impaired. This systematic review synthesises the evidence that peroxisome proliferator-activated receptor gamma agonists may be a therapeutic option to optimise clinical nutrition in critically ill patients. Method: Systematic review and meta-analysis. Results: Fourteen studies over 19 publications were included. Lean body mass was unaffected (n=174). Pioglitazone treatment resulted in periperal insulin sensitivity increasing 30-71% (Standardised mean change 0.97 (95%CI 0.36-1.58; n=213). Intramuscular Tumour Necrosis Factor Alpha concentrations decreased in treatement arms (n=29) as did circulating interlukin-6 and Tumour Necrosis Factor Alpha (n=53). Intramyocellular Lipid concentrations decreased by 34-40% with pioglitazone therapy (n=60). Treatment increased intramuscular markers of Oxidative Phosphorylation (n=55), mitochondrial biogenesis(PGC1α and PGC1β; n=26) and β-oxidation (n=29) Conclusions: Pioglitazone therapy increases skeletal muscle insulin sensitivity, decreases intramyocellular lipid accumulation and systemic and intramuscular inflammation. Where lean body mass was measured, this was seen to increase. Pioglitazone may be an adjunctive therapy to optimise clinical nutrition in acutely unwell patients. Clinical relevancy statement: Pioglitazone may optimise clinical nutrition therapy in critically ill patients by normalising carbohydrate and lipid metabolism.